Results 81 to 90 of about 10,879 (228)
American Journal of Gastroenterology, 2021 INTRODUCTION: We evaluated 8, 12, or 24 weeks of ledipasvir/sofosbuvir in patients with hepatitis C virus and end-stage renal disease undergoing dialysis.
W. Chuang +16 more
semanticscholar +1 more source
Small Molecule Targeting of Atypical p38 Protects Against Viral Infection
The FASEB Journal, Volume 39, Issue 20, 31 October 2025.Targeting host signaling pathways offers a complementary strategy to direct‐acting antivirals. Small‐molecule modulators of atypical p38 block Hepatitis C virus replication and also inhibit Human Cytomegalovirus. By disrupting virus‐induced p38 activation, these compounds suppress viral RNA replication and protein expression, highlighting atypical p38 ...
Fredejah T. Royer +6 more
wiley +1 more source
Infection and Drug Resistance, 2018 Ossama A Ahmed,1 Hany H Kaisar,1 Rehab Badawi,2 Nehad Hawash,2 Hossam Samir,1 Sherif ST Shabana,1 Mohamed Hassan A Fouad,1 Fatma H Rizk,3 Samy A Khodeir,4 Sherief Abd-Elsalam2 1Department of Internal Medicine, Faculty of Medicine, Ain Shams University ...
Ahmed OA +9 more
doaj
Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C
Anales de Pediatría, 2019 Resumen: Introducción: El objetivo del estudio fue evaluar la seguridad y la eficacia de la combinación de ledipasvir/sofosbuvir en la infección crónica por el genotipo 1 y 4 del virus de la hepatitis C (VHC) en pacientes pediátricos.
Jesús Quintero +7 more
doaj +1 more source
Multicomponent Synthesis of Fluorine‐Containing Bioactive Compounds and Drugs
European Journal of Organic Chemistry, Volume 28, Issue 38, October 15, 2025.Multicomponent reactions are robust synthetic tools to assamble complex polyheterocycles and other interesting molecular architectures with potential application in medicinal chemistry, including their fluorine‐containing analogues. Fluorine atoms placed strategically into bioactive molecules often enhance essential pharmacokinetic parameters like ...
Ivette Morales‐Salazar +7 more
wiley +1 more source
Update on hepatitis C virus resistance to direct-acting antiviral agents [PDF]
, 2014 Review[Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins.
Cachay, Edward +5 more
core +2 more sources
Journal of Clinical Medicine, 2021 Background: Available real-world data on the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in pediatric patients are limited. In this prospective, open-label, single-center study, we aimed to present our real-life experience with a fixed dose of
M. Pokorska-Śpiewak +3 more
semanticscholar +1 more source
JGH Open, Volume 9, Issue 10, October 2025.ABSTRACT Direct‐acting antivirals (DAAs) have dramatically improved sustained virological response (SVR) rates in patients with hepatitis C virus (HCV) infection. However, the risk of hepatocellular carcinoma (HCC) remains even after achieving SVR. We previously reported that alpha‐fetoprotein (AFP) levels at the end of treatment (EOT) were associated ...
Akifumi Kuwano +6 more
wiley +1 more source
F1000Research, 2020 We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen +2 more
doaj +1 more source
HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype [PDF]
, 2019 The efficacy of licensed direct-acting antiviral (DAA) regimens is assumed to be the same for hepatitis C virus (HCV)–monoinfected patients (HCV-Mono) and HIV/HCV-coinfected patients (HCV-Co). However, the high sustained viral response (SVR) rates of DAA
Albillos, Agustín +27 more
core +2 more sources